Oncology Voice Network
Join to access to all OVN content. Join for Free
Rewriting the Rules of Cellular Therapy
City of Hope Academic Research hematologic immunotherapy CAR-T cell therapy

Rewriting the Rules of Cellular Therapy

  • Jul 21st 2025
  • 47 mins
  • On the Edge of Breakthrough: Voices of Cancer Research

Share This Article

Clips

View Media
Summary

Dr. Stephen Forman shares the past, present, and future of cellular therapy and how City of Hope is building care systems to reach more patients.

In this episode of On the Edge of Breakthrough, Dr. Monty Pal is joined by Dr. Stephen Forman, a giant of cancer care and  hematologic malignancies and pioneer of cellular immunotherapy. 

Dr. Forman reflects on decades of progress in bone marrow transplantation, CAR T cell therapy, and the future of cellular therapies. But this conversation isn’t just about lab science. It’s about the human side of innovation: the infrastructure, access, and emotional support needed to truly care for patients through some of the most complex treatments in cancer care.

Dr. Forman also explains the urgency of expanding healthcare access, and reveals the  best practices for building scalable models to deliver the next-generation immunotherapy for patients who need them now.

Listen as they unpack what it means to move from an innovative experiment in the lab  to real impact on the front lines of cancer care.

Click for Source

Related Topics

See More Topics

Meet Our Innovation Partners

You May Also Like

Article
AI-powered real-world evidence: Strategically enhancing value and access
Partner Avatar Envision Pharma Group

AI-powered real-world evidence: Strategically enhancing value and access

Aug 22nd • 5 mins • read
Article
Application of Value Framework to Phase III Trials of Immune Checkpoint Inhibitors in Esophageal and Gastric Cancer
OVN Avatar Rajat Thawani, Neha Agrawal, Nicholas F Taflin, Adel Kardosh, Emerson Y Chen

Application of Value Framework to Phase III Trials of Immune Checkpoint Inhibitors in Esophageal and Gastric Cancer

Jan 13th • 8 mins • read
Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Jan 20th • 20 mins • read
Article
Mandatory Research Biopsy Requirements Delay Initiation of Clinical Trials
OVN Avatar Jonathan H. Cheng, Justin W. Tiulim, Sheng Zhou, Anthony El-Khoueiry and Jorge Nieva

Mandatory Research Biopsy Requirements Delay Initiation of Clinical Trials

Oct 18th • 10 mins • read
Article
New Realities of Phase I Clinical Trials in the Era of
OVN Avatar S.E. Abdullah, E. Oflazoglu, J.C. Soria, M.M. Dar

New Realities of Phase I Clinical Trials in the Era of

Oct 7th • 5 mins • read
Article
Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale
OVN Avatar Louis Everest, BSc; Monica Shah, BSc; Kelvin K.W. Chan, MD, MSc, PhD

Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale

Jul 10th • 12 mins • read

Explore OVN

Articles Expert-written insights
Browse Topics Oncology focus areas
OVN Podcast Flagship show
Community Why join OVN